Trial Profile
The Effect of Ivabradine Treatment on Exercise Capacity in Patients With Cardiac Allograft Vasculopathy After Heart Transplantation
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms VANISH-CAV
- 04 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 04 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.